IBRXImmunityBio, Inc.Signing up patients
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NMIBC
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 40 (planned)
- Started
- Oct 15, 2025
- Main results expected
- Feb 2028
- Fully finished
- Feb 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
The primary endpoint is to assess safety as measured by the incidence and severity of adverse events.
Measured over: Approximately 7 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06800963 · record last updated 2026-03-27 · checked 2026-11-09 15:47 UTC